Barinthus Biotherapeutics
BRNS
19 hedge funds and large institutions have $10.7M invested in Barinthus Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
6% more funds holding
Funds holding: 18 → 19 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.58% less ownership
Funds ownership: 25.4% → 24.82% (-0.58%)
9% less capital invested
Capital invested by funds: $11.8M → $10.7M (-$1.02M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.7K |
| 2 |
Millennium Management
New York
|
+$13.6K |
| 3 |
BlackRock
New York
|
+$8.7K |
| 4 |
Morgan Stanley
New York
|
+$4.17K |
| 5 |
Renaissance Technologies
New York
|
+$3.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$235K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$114K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6K |
| 4 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$671 |
BRNS Hedge Fund Activity: Q3 2024 in Review
19 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q3 2024, worth a combined $10.7M — down 8.7% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BRNS positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $15.7K. The largest seller was Baird Financial Group, cutting an estimated $235K.
- 19 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q3 2024, up from 18 in Q2 2024.
- Funds reported $10.7M of Barinthus Biotherapeutics stock for Q3 2024, down 8.7% quarter-over-quarter.
- 2 funds opened new Barinthus Biotherapeutics positions in Q3 2024 and 1 closed out, a net change of +1 holder.
- The largest Barinthus Biotherapeutics buyer in Q3 2024 was Citadel Advisors, an estimated $15.7K added.
- The largest Barinthus Biotherapeutics seller in Q3 2024 was Baird Financial Group, an estimated $235K sold.
Based on aggregated 13F filings for Q3 2024.